MOTIV Bioresorbable Scaffold in BTK Artery Disease (MOTIV BVS BTK)
Physician-initiated Trial Investigating the MOTIV™ Bioresorbable Scaffold (Reva Medical) for the Treatment of Below-The-Knee Artery Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria
- Hospital Floridsdorf
-
-
-
-
-
Arnsberg, Germany
- Klinikum Hochsauerland
-
Bad Oeynhausen, Germany
- Bad Oeyhausen Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie
-
Berlin, Germany
- Medizinische Versorgungszentren GmbH
-
Leipzig, Germany
- University Hospital Leipzig, Angiology
-
Mainz, Germany
- Katholisches Klinikum Mainz; Akademisches Lehrkrankenhaus der Johannes Gutenberg-Universität Mainz
-
Münster, Germany
- St. Franziskus-Hospital
-
Münster, Germany
- University Hospital Münster, Angiology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient presenting with rest pain or minor tissue loss (Rutherford classification from 4 to 5)
- Patient is >18 years old
- Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study - Patient has a projected life-expectancy of at least 24-months
- Patient is eligible for treatment with the MOTIV™ Bioresorbable Scaffold
- Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
- De novo lesion or Restenotic lesion after PTA in the infrapopliteal arteries, suitable for endovascular therapy
- Target vessel diameter visually estimated to be ≥2.5mm and ≤3.50mm
- Guidewire and delivery system successfully traversed the lesion
- Total target lesion is maximally 100mm
Definition of Target Lesion is:
- short de novo or Restenotic lesion after PTA or
- a short residual flow-limiting dissection or restenosis after PTA of a longer lesion
Exclusion Criteria:
- The reference segment diameter is not suitable for the available stent design
- Untreated flow-limiting aortoiliac stenotic disease
- Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment.
- Any previous surgery in the target vessel
- Aneurysm located at the target vessel
- Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy.
- Major distal amputation (above the transmetatarsal) in the study or non-study limb.
- Septicemia or bacteremia
- Any previously known coagulation disorder, including hypercoagulability
- Contraindication to anticoagulation or antiplatelet therapy
- Known allergies to scaffold or scaffold components
- Known allergies to contrast media that cannot be adequately premedicated prior to the study procedure
- Patient with known hypersensitivity to heparin-induced thrombocytopenia (HIT) type II
- Currently participating in another clinical research trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MOTIV bioresorbable vascular scaffold
MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
|
MOTIVS BVS in below-the-knee artery disease
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
efficacy endpoint - Primary Patency rate at 12-months post-op
Time Frame: 12 months post-op
|
Primary patency defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months.
|
12 months post-op
|
|
safety endpoint - rate of serious device-related adverse events within 30 days post-op
Time Frame: 30 days post-op
|
Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure.
|
30 days post-op
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Technical Success
Time Frame: 1-day post-op
|
Technical Success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%
|
1-day post-op
|
|
Primary Patency rate at follow-up visits
Time Frame: 1 month, 6 months, 12 months, 24 months and 36 months post-op
|
Primary patency rate defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months.
|
1 month, 6 months, 12 months, 24 months and 36 months post-op
|
|
Clinically-driven target lesion revascularization (TLR) at 1, 6, 12, 24 and 36-months
Time Frame: 1 month, 6 months, 12 months, 24 months and 36 months post-op
|
Clinically-driven (drop in 1 Rutherford Classification) target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the device/PTA edge
|
1 month, 6 months, 12 months, 24 months and 36 months post-op
|
|
Limb-Salvage rate at follow-up visits
Time Frame: 1 month, 6 months, 12 months, 24 months and 36 months post-op
|
Major amputation is defined as amputation at or above the ankle, as opposed to minor amputation, being an amputation at or below metatarsal level, preserving functionality of the foot.
|
1 month, 6 months, 12 months, 24 months and 36 months post-op
|
|
Clinical success at follow-up visits
Time Frame: 1 day post-op and 1 month, 6 months, 12 months, 24 months and 36 months post-op
|
Clinical success at follow-up is defined as an improvement of Rutherford classification at 1 day and 1-, 6-, 12-, 24- and 36-months follow-up of one class or more as compared to the pre-procedural Rutherford Classification.
|
1 day post-op and 1 month, 6 months, 12 months, 24 months and 36 months post-op
|
|
Serious adverse events during the study (within 36 months post-op)
Time Frame: within 36 months post-op
|
Serious adverse events as defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.
|
within 36 months post-op
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FCRE-190131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.